Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 3/2000

01-03-2000 | Review Article

Kinase Inhibitors in Cancer Therapy

A Look Ahead

Author: Dr H. H. Sedlacek

Published in: Drugs | Issue 3/2000

Login to get access

Abstract

The most essential kinases involved in cell membrane receptor activation, signal transduction and cell cycle control or programmed cell death and their interconections are reviewed. In tumours, the genes of many of those kinases are mutated or amplified or the proteins are overexpressed.
The use of key kinases offers the possibility to screen in vitro for synthetic small molecule kinase inhibitors. In view of the many interconnections of cellular kinases, their role in preventing or inducing programmed cell death and the possibility that a considerable number of signal transducing proteins are still unknown, cellular test systems are recommended in which the respective key kinase or one of its main partner molecules are overexpressed.
Literature
1.
Denn WA, Smaill JB, Fry DW, et al. Structure-activity relationships for 4-anilinoquinazoline and related pyridopyrimidine acrylamides as specific, irreversible inhibitors of the ATP site of the epidermal growth factor receptor [abstract]. Proc Am Assoc Cancer Res 1998; 39: 559
2.
Hanks SK, Hunter T. The eukaryotic protein kinase superfamily. In: Hardie G, Hanks S, editors. The protein kinase facts book. New York: Academic Press, 1995; 7: 7–47CrossRef
3.
Sedlacek HH, Hoffmann D, Schulz G, et al. The chemotherapy of malignant diseases: research perspectives. In: Sedlacek HH, Hoffmann D, Schulz G, et al., editors. Contributions to Oncology No. 34. München: Karger Verlag, 1989
4.
Plowman GD, Green JM, Culouscou JM, et al. Heregulin induces tyrosine phosphorylation of HER4/P180 (erbB4). Nature 1993; 366: 473–5PubMedCrossRef
5.
Pusztal L, Lewis CE, Lorenzen J, et al. Growth factors: regulation of normal and neoplastic growth. J Pathol 1993; 169: 191–201CrossRef
6.
Boyle WJ. Growth factors and tyrosine kinase receptors during development and cancer. Curr Opin Oncol 1992; 4: 156–62PubMedCrossRef
7.
Boulikas T. The phosphorylation connection to cancer (review). Int J Oncol 1995; 6: 271–8PubMed
8.
Cohen S, Ushiro H, Stoscheck C, et al. A native 170 000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem 1982; 257: 1523–31PubMed
9.
Gale NW, Kaplan S, Lowenstein EJ, et al. Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras. Nature 1993; 363: 88–90PubMedCrossRef
10.
Li X, Liu J, Park JK, et al. T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary report. Cancer Res 1994; 54: 5424–9PubMed
11.
Medema RH, De Vries-Smits AMM, Van Der Zon GCM, et al. Ras activation by insulin and epidermal growth factor through enhanced exchange of guanine nucleotides on p21ras. Mol Cell Biol 1993; 13: 155–62PubMed
12.
Ellis C, Moran M, McCormick F, et al. Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases. Nature 1990; 343: 377–81PubMedCrossRef
13.
Fisher DA, Lakshmanan J. Metabolism and the effects of epidermal growth factor and related growth factors in mammals. Endocr Rev 1990 11: 418–45PubMedCrossRef
14.
Velu TJ, Beguinot L, Vass WC, et al. Epidermal growth factor dependent transformation by a human EGF receptor protooncogene. Science 1987; 238: 1408–10PubMedCrossRef
15.
Downward J, Yarden Y, Mayes E, et al. Close similarity of epidermal growth factor receptor and v-erbB oncogene protein sequence. Nature 1984; 307: 521–7PubMedCrossRef
16.
Fitzpatrick SL, Brightwell J, Wittliff J, et al. Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen and progestin receptor levels. Cancer Res 1984; 44: 3448–53PubMed
17.
Klijn JGM, Berns PMJJ, Schmitz PIM, et al. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992; 13: 3–15PubMed
18.
Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol 1995; 19: 183–232CrossRef
19.
Khazaie K, Schirrmacher V, Lichtner R. EGF receptor in neoplasia and metastasis. Cancer Metast Rev 1993; 12: 255–74CrossRef
20.
21.
Fekete M, Wittliff JL, Schally AV Characteristics and distribution of receptors for [D-Trp6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 1989; 3: 137–47PubMedCrossRef
22.
Srkalovic G, Wittliff JL, Schally AV. Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 1990; 50: 1841–6PubMed
23.
Korc M, Meltzer P, Trent J. Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci U S A 1986; 83: 5141–4PubMedCrossRef
24.
Yamazaki H, Ohba Y, Tamaoki N, et al. A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor gene in human brain tumors. Jpn J Cancer Res 1990; 81: 773–9PubMedCrossRef
25.
Moscatello DK, Holgado-Madruga M, Godwin AK, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995; 55: 5536–9PubMed
26.
Wickstrand CJ, Hale LP, Batra SK, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995; 55: 3140–8
27.
Myers MG, Sun XJ, Cheatham B, et al. IRS-1 is a common element in insulin and insulin-like growth factor-I signalling to the phosphatidylinositol 3′-kinase. Endocrinol 1993; 132: 1421–30CrossRef
28.
Kern JA, Schwartz DA, Nordberg JE, et al. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990; 50: 5184–8PubMed
29.
Hall PA, Hughes CM, Staddon SL, et al. The c-erb B-2 protooncogene in human pancreatic cancer. J Pathol 1990; 161: 195–200PubMedCrossRef
30.
Berchuck A, Rodriguez G, Kinney RB, et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991; 164: 15–21PubMed
31.
Bergman CL, Hung MC, Weinberg RA. Multiple independent activation of the neu oncogene by point mutations altering the transmembrane domain of p 185. Cell 1984; 46: 649–57
32.
Radinsky R. Paracrine growth regulation of human colon carcinoma organ-specific metastasis. Cancer Metast Rev 1993; 12: 345–61CrossRef
33.
Kobrin MS, Yamanaka Y, Friess H, et al. Aberrant expression of the type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res 1993; 53: 4741–4PubMed
34.
Rudland PS, Fernig DG, Smith JA. Growth factors and their receptors in neoplastic mammary glands. Biomed Pharmacother 1995; 49: 389–99PubMedCrossRef
35.
Kato J, Wanebo H, Calabresi P, et al. Basic fibroblast growth factor production and growth factor receptors as potential targets for melanoma therapy. Melanoma Res 1992; 2: 13–23PubMedCrossRef
36.
Shih IM, Herlyn M. Autocrine and paracrine roles for growth factors in melanoma. In Vivo 1994; 8: 113–24PubMed
37.
Helle SI, Lonning PE. Insulin-like growth factors in breast and prostatic cancer. Endocr Relat Cancer 1995; 2: 153–69CrossRef
38.
39.
Bergmann U, Funtomi H, Yokoyama M, et al. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 1995; 55: 2007–11PubMed
40.
Baserga R. Controlling IGF-receptor function: a possible strategy for tumor therapy. Tibtech 1996; 14: 150CrossRef
41.
Tanaka S, Wands JR. Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor ß1-induced apoptosis. Cancer Res 1996; 56: 3391–4PubMed
42.
Ware JL. Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metast Rev 1993; 12: 287–301CrossRef
43.
Rodeck U, Herlyn M, Menssen HD, et al. Metastatic but not primary melanoma cells grow in vitro independently of exogenous growth factors. Int J Cancer 1987; 40: 687–90PubMedCrossRef
44.
Lee AV, Yee D. Insulin-like growth factors and breast cancer. Biomed Pharmacother 1995; 49: 415–21PubMedCrossRef
45.
Moody TW, Guttitta F. Growth factor and peptide receptors in small cell lung cancer. Life Sci 1993; 52: 1161–73PubMedCrossRef
46.
Rubin R, Baserga R. Insulin-like growth factor-I receptor: its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest 1995; 73: 311–31PubMed
47.
Ponzetto C, Giordano S, Della Valle G, et al. c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. Oncogene 1991; 6: 553–9PubMed
48.
Halaban R, Rubin JS, Funasaka Y, et al. Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells. Oncogene 1992; 7: 2195–206PubMed
49.
DiRenzo MF, Poulsom R, Olivero M, et al. Expression of the met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 1995; 55: 1129–38
50.
DiRenzo MF, Olivero M, Ferro S, et al. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene 1992; 7: 2549–53
51.
Stracke ML, Engel JD, Wilson LW, et al. The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells. J Biol Chem 1989; 264: 21544–9PubMed
52.
Nakagawara A, Azar CG, Scavarda NJ, et al. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994; 14: 759–67PubMed
53.
Hermansson M, Funa K, Hartman M, et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992; 52: 3213–9
54.
Nister M, Heldin CH, Wasteson A, et al. A glioma-derived analog to platelet-derived growth factor: demonstration of receptor dompeting activity and immunological crossreactivity. Proc Natl Acad Sci U S A 1984; 81: 926–30PubMedCrossRef
55.
Nister M, Libermann TA, Betsholtz C, et al. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res 1988; 48: 3910–8PubMed
56.
Claesson-Welsh L, Eriksson A, Westermark B, et al. cDNA cloning and expression of the human A-type platelet-derived growth factor (PDGF) receptor establishes structural similarity of the B-type PDGF receptor. Proc Natl Acad Sci U S A 1989; 86: 4917–21PubMedCrossRef
57.
Heldin CH, Johnsson A, Wennergren S, et l.A human osteosarcoma cell line secretes a growth factor structurally related to a homodimer of PDGF A-chains. Nature 1986; 310: 511–4CrossRef
58.
Leveen P, Claesson-Welsh L, Heldin CH, et al. Expression of messenger RNAs for platelet-derived growth factor and its receptors in human sarcoma cell lines. Int J Cancer 1990; 46: 1066–70PubMedCrossRef
59.
Werner S, Hofschneider PH, Heldin CH, et al. Cultured Kaposi’s sarcoma-derived cells express functional PDGF A-type and B-type receptors. Exp Cell Res 1990; 187: 98–103PubMedCrossRef
60.
Tsai TF, Yauk YK, Chou CK, et al. Evidence of autocrine regulation in human hepatoma cell lines. Biochem Biophys Res Commun 1988; 153: 39–45PubMedCrossRef
61.
Herlyn M, Kath R, Williams N, et a1. Growth-regulatory factors for normal, premalignant, and malignant human cells in vitro. Adv Cancer Res 1990; 54: 213–34PubMedCrossRef
62.
Ito M, Yoshida K, Kyo E, et al. Expression of several growth factors and their receptor genes in human colon carcinomas. Virchows Archiv B Cell Pathol 1990; 59: 173–8CrossRef
63.
Pantazis P, Sariban E, Bohan CA, et al. Synthesis of PDGF by cultured human T cells transformed with HTLV-I and II. Oncogene 1987; 1: 285–9PubMed
64.
Pantazis P, Kharbanda S, Goustin AS, et al. Coexpression of the genes for platelet-derived growth factor B-chain receptor and macrophage colony-stimulating factor 1 receptor during monocytic differentiation. Proc Natl Acad Sci U S A 1991; 88: 2481–5PubMedCrossRef
65.
Mäkelä TP, Alitalo R, Paulsson Y, et al. Regulation of platelet-derived growth factor gene expression by transforming growth factor beta and phorbol ester in human leukemia cell lines. Mol Cell Biol 1987; 7: 3656–62PubMed
66.
Maxwell M, Galanopoulos T, Hedley-Whyte ET, et al. Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products. Int J Cancer 1990; 46: 16–21PubMedCrossRef
67.
Peres R, Betsholtz C, Westermark B, et al. Frequent expression of growth factors for mesenchymal cells in human mammary carcinoma cell lines. Cancer Res 1987; 47: 3425–9PubMed
68.
Ginsburg E, Vonderhaar BK. Stimulation of growth of human breast cancer cells (T47D) by platelet derived growth factor. Cancer Lett 1991; 58: 137–44PubMedCrossRef
69.
70.
Collins T, Pober JS, Gimbrone MA, et al. Cultured human endothelial cells express platelet-derived growth factor A chain. Am J Pathol 1987; 126:7–12PubMed
71.
Roussel MF, Downing JR, Rettenmier CW, et al. A point mutation in the extracellular domain of the human CSF-1 receptor (Fms proto-oncogene product) activates its transforming potential. Cell 1988; 55: 979–88PubMedCrossRef
72.
Yokoyama Y, Morishita S, Takahashi Y, et al. Modulation of c-fms proto-oncogene in an ovarian carcinoma cell line by a hammerhead ribozyme. Br J Cancer 1997; 76: 977–82PubMedCrossRef
73.
Suzuki M, Sekiguchi I, Ohwada M, et al. Expression of c-fms proto-oncogene product by ovarian cancer cell lines with effects of macrophage colony-stimulating factor on proliferation. Oncology 1996; 53: 99–103PubMedCrossRef
74.
Sapi E, Flick MB, Gilmore-Hebert M, et al. Transcriptional regulation of the c-fms (CSF-1R) proto-oncogene in human breast carcinoma cells by glucocorticoids. Oncogene 1995; 10: 529–42PubMed
75.
Chambers SK, Wang Y, Gilmore-Hebert M, et al. Post-transcriptional regulation of c-fms proto-oncogene expression by dexamethasone and of CSF-1 in human breast carcinomas in vitro. Steroids 1994; 59: 514–22PubMedCrossRef
76.
Scholl SM, Mosseri V, Tang R, et al. Expression of colony-stimulating factor-1 and its receptor (the protein product of c-fms) in invasive breast tumor cells: induction of urokinase production via this pathway? Ann N Y Acad Sci 1993; 698: 131–5PubMedCrossRef
77.
Kacinski BM, Scata KA, Carter D, et al. FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. Oncogene 1991; 6: 941–52PubMed
78.
Leiserowitz GS, Harris SA, Subramaniam M, et al. The protooncogene c-fms is overexpressed in endometrial cancer. Gynecol Oncol 1993; 49: 190–6PubMedCrossRef
79.
Storga D, Pecina-Slaus N, Pavelic J, et al. c-fms is present in primary tumours as well as in their metastases in bone marrow. Int J Exp Pathol 1992; 73: 527–33PubMed
80.
Qui F, Ray R, Brown K, et al. Primary structure of cKit: relationship with the CSF-1/PDGF receptor kinase family. Oncogenic activation of vKit involves deletion of extracellular domain and C-terminus. EMBO J 1988; 7: 1003–11
81.
Funasaka Y, Boulton T, Cobb M, et al. c-kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor in stimulates mitogen-activated protein kinase but is down-regulated in melanomas. Mol Biol Cell 1992; 3: 197–209PubMed
82.
Natali PG, Nicotra MR, Winkler AB, et al. Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 1992; 52: 197–201PubMedCrossRef
83.
Lassam N, Bickford S. Loss of c-kit expression in cultured melanoma cells. Oncogene 1992; 7: 51–6PubMed
84.
Charnock-Jones DS, Sharkey AM, Boocock AM, et al. Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells. Biol Reproduct 1994; 51: 524–30CrossRef
85.
Gitay-Goren H., Halaban R, Neufeld G, et al. Human melanoma cells but not nor normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun 1993; 190: 702–9PubMedCrossRef
86.
Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995; 87: 506–16PubMedCrossRef
87.
Brown LF, Berse B, Jackman RW, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993; 143: 1255–62PubMed
88.
Enomoto T, Okamoto T, Sato JD. Vascular endothelial growth factor induces the disorganization of actin stress fibers accompanied by protein tyrosine phosphorylation and morphological change in Balb/C3T3 cells. Biochem Biophy Res Commun 1994; 202: 1716–23CrossRef
89.
Katoh O, Tauchi H, Kawaishi K, et al. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 1995; 55: 5687–92PubMed
90.
Soker S, Takahima S, Mia HQ, et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 735-45
91.
Koura AN, Liu W, Kitadai Y, et al. Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by cell density. Cancer Res 1996; 56: 3891–4PubMed
92.
Brown K, Gerstbergre S, Carlson L, et al. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 1995; 267: 1485–8PubMedCrossRef
93.
Takahashi T, Shibuya M. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLCγ pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 1997; 14: 2079–89PubMedCrossRef
94.
Berse B, Brown LF, Van De Water L, et al. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992; 3: 211–20PubMed
95.
Dhingra K, Horn S, Sahin A, et al. Expression of TIE-2 receptor and ligand in human cell lines and tumor biopsy specimens [abstract]. Proc Annu Meet Am Assoc Cancer Res 1997; 38: A3260
96.
Chang J, Park K, Bang YJ, et al. Expression of transforming growth factor ß type II receptor reduces tumorigenicity in human gastric cancer cells. Cancer Res 1997; 57: 2856–9PubMed
97.
Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-ß receptor in colon cancer cells with microsatellite instability. Science 1995; 268: 1336–8PubMedCrossRef
98.
Kadin M, Cavaille-Coll MW, Gertz R, et al. Loss of receptors for transforming growth factor ß receptors: role in physiology and disease. J Biomed Sci 1996; 3: 143–58CrossRef
99.
Kim IY, Ahn HJ, Zelner DJ, et al. Genetic change in transforming growth factor ß (TGF-ß) receptor type I gene correlates with insensitivity to RGF-ß1 in human prostate cancer cells. Cancer Res 1996; 56: 44–8PubMed
100.
Parsons R, Myerhoff LL, Liu BL, et al. Microsatellite instability and mutations of the transforming growth factor ß type II receptor gene in colorectal cancer. Cancer Res 1995; 55: 5548–50PubMed
101.
Myeroff LL, Parsons R, Kim SJ, et al. A transforming growth factor ß receptor type II gene mutation common in colon and gastric but rare in endomietric cancers with microsatellite instability. Cancer Res 1995; 55: 5545–7PubMed
102.
Easty DJ, Ganz SE, Farr CJ, et al. Novel and known protein tyrosine kinases and their abnormal expression in human melanoma. J Invest Dermatol 1993; 101: 679–84PubMedCrossRef
103.
Boyd AW, Ward LD, Wicks IP, et al. Isolation and characterization of a novel receptor-type protein tyrosine kinase (hek) from a human pre-B cell lines. J Biol Chem 1992; 267: 3262–7PubMed
104.
Wicks IP, Wilkinson D, Salvaris E, et al. Molecular cloning of HEK the gene encoding a receptor tyrosine kinase expressed by human lymphoid tumor cell lines. Proc Natl Acad Sci U S A 1992; 89: 1611–5PubMedCrossRef
105.
Easty DJ, Guthrie BA, Maung K, et al. Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. Cancer Res 1995; 55: 2528–32PubMed
106.
Maru Y, Hirai H, Yoshida MC, et al. Evolution, expression and chromosomal location of a novel receptor tyrosine kinase gene. Mol Cell Biol 1988; 8: 3770–6PubMed
107.
Carlomagno F, Savatore D, Santoro M, et al. Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 1995; 207: 1022–8PubMedCrossRef
108.
Sugg SL, Zheng L, Rosen IB, et al. ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential? J Clin Endocrin Metab 1996; 81: 3360–5CrossRef
109.
Takaya K, Yoshimasa T, Arai H, et al. Expression of the RET proto-oncogene in normal human tissues, pheochromocytomas, and other tumors of neural crest origin. J Mol Med 1996; 74: 617–21PubMedCrossRef
110.
Nakamura T, Ishizaka Y, Nagao M, et al. Expression of the ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin. J Pathol 1994; 172: 255–60PubMedCrossRef
111.
Ivanchuk S, Eng C, Myers S, et al. Expression of alternatively spliced RET transcripts in the developing human kidney and Wilm’s tumor. Am J Hum Genet 1995; 57: A302
112.
Mapstone T, McMichael M, Goldthwait D. Expression of platelet-derived growth factors, transforming growth factors, and the ros gene in a variety of primary human brain tumors. Neurosurgery 1991; 28: 216–22PubMedCrossRef
113.
Watkins D, Dion F, Poisson M, et al. Analysis of oncogene expression in primary human gliomas: evidence for increased expression of the ros oncogene. Cancer Genet Cytogenet 1994; 72: 130–6PubMedCrossRef
114.
Wu JK, Chikaraishi DM, Differential expression of ros oncogene in primary human astrocytomas and astrocytoma cell lines. Cancer Res 1990; 50: 3032–5PubMed
115.
Dickson RB, Lippman ME. Growth factors in breast cancer. Endocrine Rev 1995; 16: 559
116.
Nicholson RI, McClelland RA, Gee JMW, et al. Transforming growth factor-α and endocrine sensitivity in breast cancer. Cancer Res 1994; 54: 1684–9PubMed
117.
Barrett-Lee P, Travers M, Luqmani Y, et al. Transcripts fortransforming growth factors in human breast cancer: clinical correlates. Br J Cancer 1990; 61: 612–7PubMedCrossRef
118.
Murphy LC, Dotslaw H, Wong MSJ. Epidermal growth factor: receptor and ligand expression in human breast cancer. Semin Cancer Biol 1990; 1: 305–15PubMed
119.
Murray PA, Barrett-Lee P, Travers M, et al. The prognostic significance of transforming growth factors in human breast cancer. Br J Cancer 1993; 67: 1408–12PubMedCrossRef
120.
Semba K, Kamata N, Toyoshima K, et al. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci U S A 1985; 82: 6497–501PubMedCrossRef
121.
Plowman GD, Culouscou JM, Whitney GS, et al. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci US A 1993; 90: 1746–50CrossRef
122.
Carraway KL, Cantley LC. A new acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signalling. Cell 1994; 78: 5–8PubMedCrossRef
123.
Goldman R, Levy RB, Peles E, et al. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry 1990; 29: 11024–8PubMedCrossRef
124.
Qian X, Decker SJ, Greene MI. p185c-neu and epidermal growth factor receptor associate into a structure composed of activated kinases. Proc Natl Acad Sci U S A 1992; 89: 1330–4CrossRef
125.
Soltoff SP, Carraway KL, Prigent SA, et al. ErbB3 is involved in activating phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994; 14: 3550–8PubMed
126.
Lee PL, Johnson DE, Cousens LS, et al. Purification and cDNA cloning of a receptor for basic fibroblast growth factor. Science 1989; 245: 57–60PubMedCrossRef
127.
Kornbluth S, Paulson DE, Hanafusa H. Novel tyrosine kinase identified by phosphotyrosine antibody screening of cDN libraries. Mol Cell Biol 1988; 8: 5541–4PubMed
128.
Keegan K, Johnson DE, Williams LT, et al. Isolation of an additional member of the fibroblast growth factor receptor family FGFR-3. Proc Natl Acad Sci U S A 1991; 88: 1095–9PubMedCrossRef
129.
Partanan J, Makla TP, Eerola E, et al. FGFR-4,, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. EMBO J 1991; 10: 1347–54
130.
Avivi A, Zimmer Y, Yayon A, et al. Flg-2, a new member of the family of fibroblast growth factor receptors. Oncogene 1991; 6: 1089–92PubMed
131.
Yan G, Fukabori Y, Nikolaropoulos S, et al. Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial cell andromedin. Mol Endocrinol 1992; 6: 2123–8PubMedCrossRef
132.
Yan G, Fukabori Y, McBride G, et al. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF): FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 1993; 13: 4513–22PubMed
133.
Dvorak HF, Sioussat TM, Brown LF, et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 1991; 174: 1275–8PubMedCrossRef
134.
Plate KH, Breier G, Weich HA et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845–8PubMedCrossRef
135.
Heldin CH, Westermark B. Platelet-derived growth factor: mechanism of action and possible in vivo function. Cell Regul 1990; 1: 555–66PubMed
136.
Bywater M, Rorsman F, Bongcam-Rudloff E, et al. Expression of recombinant platelet-derived growth factor A- and B -chain homodimers in Rat-1 cells and human fibroblasts reveals differences in protein processing and autocrine effects. Mol Cell Biol 1988; 8: 2753–62PubMed
137.
Keating MT, Williams LT. Autocrine stimulation of intracellular PDGF receptors in v-sis transformed cells. Science 1988; 239: 914–6PubMedCrossRef
138.
Huang SS, Huang JS. Rapid turnover of the platelet-derived growth factor receptor in sis-transformed cells and reversal by suramin: implications for the mechanism of autocrine transformation. J Biol Chem 1988; 263: 12608–18PubMed
139.
Westermark B, Heldin CH. Platelet-derived growth factor in autocrine transformation. Cancer Res 51: 5087-92
140.
Ponten F, Ren Z, Nister M, et al. Epithelial-stromal interactions in basal cell cancer: the PDGF system. J Invest Dermatol 1994; 102: 304–9PubMedCrossRef
141.
Funa K, Papanicolaou V, Juhlin C, et al. Expression of platelet-derived growth factor beta-receptors on stromal tissue cells in human carcinoid tumors. Cancer Res 1990; 50: 748–53PubMed
142.
Chaudhry A, Panpanicolaou V, Oberg K, et al. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res 1992; 52: 1006–12PubMed
143.
Sato N, Nariuchi H, Tsuruoka N, et al. Actions of TNF and IFN-gamma on angiogenesis in vitro.J Invest Dermatol 1990; 95: 85S–89SPubMedCrossRef
144.
Hermansson M, Nister M, Betsholtz C, et al. Endothelial cell hyperplasia in human glioblastoma: co-expression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. Proc Natl Acad Sci U S A 1988; 85: 7748–52PubMedCrossRef
145.
Beitz JG, Kim IS, Calabrese P, et al. Human microvascular endothelial cells express receptors for platelet-derived growth factor. Proc Natl Acad Sci U S A 1991; 88: 2021–5PubMedCrossRef
146.
Shibuya M, Yamguchi S, Yamane A, et al. Nucleotide sequences and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fins family. Oncogene 1990; 5: 519–24PubMed
147.
DeVries C, Escobedo JA, Ueono H, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989–91CrossRef
148.
Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187: 1579–86PubMedCrossRef
149.
Millauer B, Wizigmann-Voos S, Schnurch H, et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72: 835–46PubMedCrossRef
150.
Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases [published errata appears in EMBO J 1996; 15: 1751]. EMBO J 1996; 15: 290–8PubMed
151.
Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269: 26988–95PubMed
152.
Yoshida A, Anand-Apte B, Zetter BR. Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors 1996; 13: 57–64PubMedCrossRef
153.
Ferrara N, Davis-Smith T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4–25PubMedCrossRef
154.
Peters KG, DeVries C, Williams LT. Vascular endothelial growth factor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. Proc Natl Acad Sci U S A 1993; 90: 8915–9PubMedCrossRef
155.
Fong GH, Rossant J, Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66–70PubMedCrossRef
156.
Guo D, Jia Q, Song HY, et al. Vascular endothelial cells growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains: association with endothelial cell proliferation. J Biol Chem 1995; 270: 6729–33PubMedCrossRef
157.
Kroll J, Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 1997; 272: 32521–7PubMedCrossRef
158.
Igarashi K, Shigeta K, Isohara T, et al. Sck interacts with KDR and Flt-1 via its SH2 domain. Biochem Biophys Res Commun 1998; 251: 77–82PubMedCrossRef
159.
Igarashi K, Isohara T, Kato T, et al. Tyrosine 1213 of Flt-1 is a major binding site of Nck and SHP-2. Biochem Biophys Res Commun 1998; 246: 95–9PubMedCrossRef
160.
Mukhopadhyay D, Nagy JA, Manseau EJ, et al. Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium. Cancer Res 1998; 58: 1278–84PubMed
161.
Clauss M, Gerlach M, Brett J, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172: 1535–45PubMedCrossRef
162.
Gruber BL, Marchese MJ, Kew R. Angiogenic factors stimulate mast-cell migration. Blood 1995; 86: 2488–93PubMed
163.
Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87 3336–43PubMed
164.
Seetharam L, Gotoh N, Mara Y, et al. A unique signal transduction from FlT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 1995; 10: 135–47PubMed
165.
Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 1309–12PubMedCrossRef
166.
Leung DL, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1996; 246: 1306–9CrossRef
167.
Plouet J, Schilling J, Gospodarowicz D. Isolation and characterization of newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 1989; 8: 3801–6PubMed
168.
Midy V, Plouet J. Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts. Biochem Biophys Res Commun 1994; 199: 380–6PubMedCrossRef
169.
Ullrich A, Gray A, Tam AW, et al. Insulin-like growth factor 1 receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986; 5: 2503–12PubMed
170.
Werner H, Woloschak M, Stannard B, et al. The insulin-like growth factor receptor: molecular biology, heterogeneity and regulation. In: LeRoith D, editor. Insulin-like growth factors: molecular and cellular aspects. Boca Raton (FL): CRC Press, 1991: 17–47
171.
Lowe WL. Biological actions of the insulin-like growth factors. In: Le Roith D, editor. Insulin-like growth factors: molecular and cellular aspects. Boca Raton (FL): CRC Press, 1991: 49–85
172.
Huang S, Terstappen LWMM. Formation of haematopoietic microenvironment and haematopoietic stem cells from single human bone marrow stem cells. Nature 1992; 360: 745–9PubMedCrossRef
173.
Goldring MB, Goldring SR. Cytokines and cell growth control. Crit Rev Eukaryot Gene Expr 1991; 1: 301–26PubMed
174.
Condorelli G, Bueno R, Smith RJ. Two alternatively spliced forms of the human insulin-like growth factor I receptor have distinct biological activities and internalization kinetics. J Biol Chem 1994; 269: 8510–6PubMed
175.
Ota A, Wilson GL, Le Roith D. Insulin-like growth factor I receptors on mouse neuroblastoma cells: two beta subunits are derived from differences in glycosylation. Eur J Biochem 1988; 174: 521–30PubMedCrossRef
176.
Tavare JM, Siddle K. Mutational analysis of insulin receptor function: consensus and controversy. Biochim Biophys Acta 1993; 1178: 21–39PubMedCrossRef
177.
Siddle K, Soos, MA, Field CE, et al. Hybrid and atypical insulin/insulin-like growth factor I receptors. Hormone Res 1994; 41: 56–65PubMedCrossRef
178.
Sun XJ, Rothenberg P, Kahn CR, et al. The structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 1991; 352: 73–7PubMedCrossRef
179.
Sun XJ, Miralpeix M, Myers MG, et al. The expression and function of IRS-1 in insulin signal transmission. J Biol Chem 1992; 267: 22662–72PubMed
180.
Giorgetti S, Ballotti R, Kowalski-Chauvel A, et al. The insulin and insulin-like growth factor-1 receptor substrate IRS-1 associates with and activates phosphatidylinositol 3-kinase in vitro. J Biol Chem 1993; 268: 7358–64PubMed
181.
Yamauchi K, Pessin JE. Insulin receptor substrate-1 (IRSl)and Shc compete for a limited pool of Grb2 in mediating insulin downstream signalling. J Biol Chem 1994; 269: 31107–14PubMed
182.
Sasaoka T, Rose DW, Jhun BH, et al. Evidence for a functional role of Shc proteins in mitogenic signalling induced by insulin, insulin-like growth factor-1, and epidermal growth factor. J Biol Chem 1994; 269: 13689–94PubMed
183.
Heitner-Johnson D, LeRoith D. Insulin-like growth factor-I stimulated tyrosine phosphorylation of endogenous c-Crk. J Biol Chem 1995; 290: 5187–90
184.
Matsuda M, Hshimoti Y, Muroya K, et al. CRK protein binds to two guanine nucleotide-releasing proteins for the Ras family and modulates nerve growth factor-induced activation of Ras in PC12 cells. Mol Cel Biol 1994; 14: 5495–500
185.
Clemmons DR, Van Wyk JJ. Somatomedin: physiological control and effects on cell proliferation. In: Baserga R, editor. Tissue growth factors. Berlin: Springer-Verlag KG, 1981; 161CrossRef
186.
Clemmons DR, Shaw DS. Variables controlling somatomedin production by cultured human fibroblasts. J Cell Physiol 1983; 115: 137–42PubMedCrossRef
187.
Baserga R, Sell C, Porcu P, et al. The role of the IGF-I receptor in the growth and transformation of mammalian cells. Cell Prolif 1994; 27: 63–71PubMedCrossRef
188.
Pietrzkowski Z, Wernicke D, Porcu P, et al. Inhibition of cell proliferation by peptide analogs of IGF-1. Cancer Res 1992; 52: 6447PubMed
189.
Travali S, Reiss K, Ferber A, et al. Constitutively expressed c-myb abrogates the requirement for insulin-like growth factor I in 3T3 fibroblasts. Mol Cell Biol 1991; 11: 731–6PubMed
190.
Reiss K, Ferger A, Travali S, et al. The proto-oncogene c-myb increases the expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor messenger RNAs by a transcriptional mechanism. Cancer Res 1991; 51: 5997–6000PubMed
191.
Pietrzkowski Z, Lammers, R, Carpenter G, et al. Constitutive expression of insulin-like growth factor 1 and insulin-like growth 1 receptor abrogates all requirements for exogenous growth factors. Cell Growth Differ 1992; 3: 199–205PubMed
192.
Porcu P, Ferber A, Pietrzkowski Z, et al. The growth-stimulatory effect of Simian virus 40 T antigen requires the interaction of insulin-like growth factor 1 with its receptor. Mol Cell Biol 1992; 12: 5069–77PubMed
193.
Reiss K, Porcu P, Sell C, et al. The insulin-like growth factor 1 receptor is required for the proliferation of hematopoietic cells. Oncogene 1992; 7: 2243–8PubMed
194.
Resnicoff M, Sell C, Rubini M, et al. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-I (IGF-I) receptor are non-tumorigenic and induce of wild type tumors. Cancer Res 1994; 54: 2218–22PubMed
195.
Pietrzkowski Z, Mulholland G, Gomella L, et al. Inhibition of growth of prostatic cancer cell lines by peptide analogs of IGF-1. Cancer Res 1993; 53: 1102–6PubMed
196.
Sell C, Rubini M, Rubin R, et al. Simian viras 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type-I IGF receptor. Proc Natl Acad Sci U S A 1993; 90: 11217–21PubMedCrossRef
197.
Baserga R, Sell C, Porcu P, et al. The role of the IGF-I receptor in the growth and transformation of mammalian cells. Cell Prolif 1994; 27: 63–71PubMedCrossRef
198.
Kan M, Zhang G, Zarnegar R, et al. Hepatocyte growth factor/hepatopoietin A stimulates the growth of rat kidney proximal tubule epithelial cells (RPTE), rat nonparenchymal liver cells, human melanoma cells, mouse keratinocytes and stimulates anchorage-independent growth of SV40-transformed RPTE. Biochem Biophys Res Commun 1991; 174: 331–7PubMedCrossRef
199.
Stoker M, Gherardi E, Perryman M, et al. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987; 327: 239–342PubMedCrossRef
200.
Bussolino F, Di Renzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992; 119: 629–41PubMedCrossRef
201.
Grant DS, Kleinman, HK, Goldberg ID, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A 1993; 90: 1937–41PubMedCrossRef
202.
Weidner KM, Behrens J, Vanderkerckhone J, et al. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol 1990; 111: 2907–11CrossRef
203.
Weidner KM, Hartmann G, Naldini L, et al. Molecular characteristics of HGF/SF and its role in cell motility and invasion. EXS 1993; 65: 311–28PubMed
204.
Giordano S, Ponzetto D, Di Renzo MF, et al. Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 2989; 339: 155–6CrossRef
205.
Gonzatti-Haces M, Seth A, Park M, et al. Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein tyrosine kinases. Proc Natl Acad Sci U S A 1988; 85: 21–5PubMedCrossRef
206.
Prat M, Crepaldi T, Gandino L, et al. C-terminal truncated forms of Met, the hepatocyte growth factor receptor. Mol Cell Biol 1991; 11: 5954–60PubMed
207.
Crepaldi T, Prat M, Giordano S, et al. Generation of a truncated hepatocyte growth factor receptor in the endoplasmic reticulum. J Biol Chem 1994; 269: 1750–5PubMed
208.
Cooper CS. HGFR. In: Hardie G, Hanks S, editors. The protein kinase facts book. New York: Academic Press, 1995: 218–20CrossRef
209.
210.
Callard RE, Gearing AJH. The cytokine facts book. London: Academic Press, 1994
211.
Lin H, Wang XF, Ng-Eaton E, et al. Expression cloning of the TGF-ß type II receptor a functional transmembrane serine/threonine kinase. Cell 1992; 68: 775–85PubMedCrossRef
212.
Wrana JL, Attisano L, Carcamo J, et al. TGF-ß signals through a heteromeric protein kinase receptor complex. Cell 1992; 71: 1003–14PubMedCrossRef
213.
Kekow J, Wiedemann GJ. Transforming growth factor ß: a cytokine with multiple actions in oncology and potential clinical applications [review]. Int J Oncol 1995; 7: 177–82PubMed
214.
Heldin CH, Miyazono K, ten Dijke P. TGFß-signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390: 465–71PubMedCrossRef
215.
Yamashita H, ten Dijke P, Franzen P, et al. Formation of heterooligomeric complexes of type I and type II receptors for transforming growth factor-ß. J Biol Chem 1994; 269: 20172–8PubMed
216.
Souchelnytskyi S, Tamaki K, Engstom U, et al. Phosphorylation of Ser465 and Ser467 in the C-terminus of Smad2 mediates interaction with Smad4 and is required for TGF-ß signalling. J Biol Chem 1997; 272: 28107–15PubMedCrossRef
217.
Nakao A, Afrakhte M, Moren A, et al. Identification of Smad7, a TGFß-inducible antagonist of TGF-ß signalling. Nature 1997; 389: 631–5PubMedCrossRef
218.
Imamura T, Takase M, Nishihara A, et al. Smad6 inhibits signalling by the TGF-ß superfamily. Nature 1997; 389: 622–6PubMedCrossRef
219.
220.
Powell SM, Harper JC, Hamilton SR, et al. Inactivation of Smad4 in gastric carcinomas. Cancer Res 1997; 57: 4221–4PubMed
221.
Riggins GJ, Kinzler KW, Vogelstein B, et al. Frequency of Smad gene mutations in human cancers. Cancer Res 1997; 57: 2578–80PubMed
222.
Battegay EJ, Raines EW, Seifert RA, et al. TGF-ß induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 1990; 63: 515–24PubMedCrossRef
223.
Luttrell DK, Lee A, Lansing TJ, et al. Involvement of pp60c-src with two major signaling pathways in human breast cancer. Proc Natl Acad Sci U S A 1994; 91: 83–7PubMedCrossRef
224.
Maa MC, Leu TH, McCarley DJ, et al. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: Implications for the etiology of multiple human cancers. Proc Natl Acad Sci U S A 1995; 92: 6981–5PubMedCrossRef
225.
Wilson LK, Luttrell DK, Parsons JT, et al. pp60c-src tyrosine kinase, myristylation, and modulatory domains are required for enhanced mitogenic responsiveness to epidermal growth factor seen in cells overexpressing c-src. Mol Cell Biol 1989; 9: 1536–44PubMed
226.
Bolen JB. Nonreceptor tyrosine protein kinases. Oncogene 1993; 8: 2025–31PubMed
227.
Chang JH, Wilson LK, Moyers JS, et al. Increased levels of p21ras-GTP and enhanced DNA synthesis accompany elevated tyrosyl phosphorylation of GAP-associated proteins, p190 and p62, in c-src overexpressors. Oncogene 1993; 8: 959–67PubMed
228.
Maa MC, Wilson LK, Moyers JS, et al. Identification and characterization of a cytoskeleton-associated, epidermal growth factor sensitive pp60c-src substrate. Oncogene 1992; 7: 2429–38PubMed
229.
Hardie G, Hanks S, editors. The protein kinase facts book. New York: Academic Press, 1995
230.
Zhang W, Sloan-Lancaster J, Kitchen J, et al. LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell 1998; 92: 83–92PubMedCrossRef
231.
Cartwright CA, Kamps MP, Meisler AI, et al. pp60c-src activation in human colon carcinoma. J Clin Invest 1989; 3: 2025–33CrossRef
232.
Ottenholf-Kaliff AE, Rijksen G, van Beurden EA, et al. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res 1992; 52: 4773–8
233.
Rosen N, Bolen JB, Schwartz AM, et al. Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem 1986; 261: 13754–9PubMed
234.
Park J, Cartwright CA. Src activity increases and Yes activity decreases during mitosis of human colon carcinoma cells. Mol Cell Biol 1995; 15: 2374–82PubMed
235.
Park J, Meisler AI, Cartwright CA. c-Yes tyrosine kinase activity in human colon carcinoma. Oncogene 1993; 8: 2627–35PubMed
236.
Han NM, Curley SA, Gallick GE. Differential activation of pp60c-src and pp62c-yes in human colorectal carcinoma liver metastases. Clin Cancer Res 1996; 2: 1397–404PubMed
237.
Willman CL, Stewart CC, Longacre TL, et al. Expression of the c-fgr and hck protein-tyrosine kinases in acute myeloid leukemic blasts is associated with early commitment and differentiation events in the monocytic and granulocytic lineages. Blood 1991; 77: 726–34PubMed
238.
Krueger J, Zhao YH, Murphy D, et al. Differential expression of p62c-yes in normal, hyperplastic and neoplastic human epidermis. Oncogene 1991; 6: 933–40PubMed
239.
Seki T, Fujii G, Mori S, et al. Amplification of c-yes-1 protooncogene in a primary human gastric cancer. Jpn J Cancer Res 1985; 76: 907–10PubMed
240.
Abts H, Juecker M, Diehl V, et al. Human chronic lymphocytic leukemia cells regularly express mRNAs of the protooncogenes lck and c-fgr. Leuk Res 1991; 15: 987–97PubMedCrossRef
241.
von Knethen A, Abts H, Kube D, et al. The expression of the P56-LCK proto-oncogene in B-cell lineage neoplasias. Ann Hematol 1993; 67: A66
242.
Rouer E, Dreyfus F, Melle J, et al. Selective increase of alternatively spliced Lck transcripts from the proximal promoter in hematopoietic malignancies. Leukemia 1993; 7: 246–50PubMed
243.
Juecker M, Abts H, Eick D, et al. Over-expression of lck in Burkitt’s lymphoma cell lines [letter]. Leukemia 1991; 5: 528–30
244.
Burnett RC, David JC, Harden AM, et al. The LCK gene is involved in the t(1;7)(p34;q34) in the T-cell acute lymphoblastic leukemia derived cell line, HSB-2. Genes, Chromosomes Cancer 1991; 3: 461–7PubMedCrossRef
245.
Koga Y, Kimura N, Minowada J, et al. Expression of the human T-cell-specific tyrosine kinase YT16 (lck) message in leukemic T-cell lines. Cancer Res 1988; 48: 856–9PubMed
246.
Nakamura K, Chijiiwa Y, Nawata H. Augmented expression of LCK message directed from the downstream promoter in human colorectal cancer specimens. Eur J Cancer 1996; 32A: 1401–7PubMedCrossRef
247.
Mayer K, Ballhausen WG. Expression of alternatively spliced lck transcripts from the proximal promoter in colorectal cancer derived cell lines. Anticancer Res 1996; 16: 1733–7PubMed
248.
Veilette A, Foss FM, Sausville EA, et al. Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines. Oncogene Res 1987; 1: 357–74
249.
McCracken S, Kim CS, Xu Y, et al. An alternative pathway of expression of p56-lck from type I promoter transcripts in colon carcinoma. Oncogene 1997; 15: 2929–37PubMedCrossRef
250.
Foss FM, Veillette A, Sartor O, et al. Alterations in the expression of pp60(c-src) an p56(lck) associated with butyrate-induced differentiation of human colon carcinoma cells. Oncogen Res 1989; 5: 13–23
251.
Nowell PC, Hungerford DA. A minute chromosome in human granulocyte leukemia. Science 1960; 132: 1497–500
252.
Zarn JA, Zimmermann SM, Pass MK, et al. Association of CD24 with the kinase c-fgr in a small cell lung cancer cell line and with the kinase lyn in an erythroleukemia cell line. Biochem Biophys Res Commun 1996; 225: 384–91PubMedCrossRef
253.
Tesch H, Abst H, Juecker M, et al. Expression of c-fgr in EBV positive and negative B cell tumors. Leukemia 1989; 3: 897–8PubMed
254.
Cheah MS, Ley TJ, Tronick SR, et al. fgr proto-oncogene mRNA induced in B lymphocytes by Epstein-Barr virus infection. Nature 1986; 319: 238–40PubMedCrossRef
255.
Faulkner L, Katz DR, Brickell PM. Retinoic acid induces changes in c-fgr proto-oncogene mRNA levels in Burkitt’s lymphoma cells. Immunobiology 1993; 188: 460–8PubMedCrossRef
256.
Sharp NA, Luscombe MJ, Clemens MJ. Regulation of c-fgr proto-oncogene expression in Burkitt’s lymphoma cells: effect of interferon treatment and relationship to EBV status and c-myc mRNA levels. Oncogene 1989; 4: 1043–6PubMed
257.
Nishio H, Nakamura S, Horai T, et al. Clinical and histopathologic evaluation of the expression of Ha-ras and fes oncogene products in lung cancer. Cancer 1992; 69: 1130–6PubMedCrossRef
258.
Goldman J, Kowalczuk MM, Lafuze JE. Detection of a putative fusion product formed from tumor necrosis factor receptor (TNFR) and the FES/FPS oncogene from probing of two adolescent T-cell ALL substracted cDNA libraries [abstract]. Proc Am Assoc Cancer Res 1994; 35: A3483
259.
Morris C, Heisterkamp N, Hao QL, et al. The human tyrosine kinase gene (FER) maps to chromosome 5 and is deleted in myeloid leukemias with a del(5q). Cytogenics Cell Genet 1990; 53: 196–200CrossRef
260.
Takemoto S, Mulloy JC, Cereseto A, et al. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci US A 1997; 94: 13897–902CrossRef
261.
Meydan N, Grunberger T, Dadi H, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996; 379: 645–8PubMedCrossRef
262.
Ratovitski EA, Kotzbauer PT, Milbrandt J, et al. Midkine induces tumor cell proliferation and binds to a high affinity signaling receptor associated with JAK tyrosine kinases. J Biol Chem 1998; 273: 3654–60PubMedCrossRef
263.
Murata T, Noguchi PD, Puri RK. IL-13 induces phosphorylation and activation of Jak2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-12 signaling. J Immunol 1996; 156: 2972–8PubMed
264.
Okamoto H, Nakamori S, Ohigashi H, et al. Involvement of focal adhesion kinase (FAK) in endothelial cell retraction during cancer cell invasion [abstract]. Proc Annu Meet Am Assoc Cancer Res 1997; 38: A349
265.
Hubbard SL, Dirks P, Murakami M, et al. Expression of focal adhesion kinase (FAK) in human astrocytoma cell lines and brain tumors [abstract]. Proc Annu Meet Am Assoc Cancer Res 1996; 37: A315
266.
Weiner TM, Liu ET, Cance WG. Overexpression of the focal adhesion kinase (FAK) gene in primary and metastatic human tumors [abstract]. 46th Annual Cancer Symposium of the Society of Surgical Oncology in Conjunction with Society of Head and Neck Surgeons; 1993 March 18–21; Los Angeles: 7
267.
Owens LV, Xu L, Craven RJ, et al. Overexpression of the focal adhesion kinase (p125-FAK) in invasive human tumors. Cancer Res 1995; 55: 2752–5PubMed
268.
Han NM, Fleming RYD, Curley SA, et al. Overexpression of focal adhesion kinase (P125(FAK)) in human colorectal-carcinoma liver metastases: independence from c-src or c-yes activation. Ann Surg Oncol 1997; 4: 264–8PubMedCrossRef
269.
Judson PL, He X, Cance WG, et al. FAK, a tyrosine kinase implicated in invasion and metastasis, is overexpressed in ovarian carcinoma. Gynecol Oncol 1998; 68: 82
270.
Jenq WM, Cooper DR, Ramirez G. Integrin expression on cell adhesion function and up-regulation of P125-FAK and paxillin in metastatic renal carcinoma cells. Mol Biol Cell 1996; 7: 424A
271.
Tremblay L, Hauck W, Aprikian AG, et al. Focal adhesion kinase (pp125-FAK) expression, activation and association with paxillin and p50-csk in human metastatic prostate carcinoma. Int J Cancer 1996; 68: 164–71PubMedCrossRef
272.
Akasaka T, Van Leeuwen RL, Yoshinaga IG, et al. Focal adhesion kinase (p125(FAK)) expression correlates with motility of human melanoma cell lines. J Invest Dermatol 1995; 105: 104–8PubMedCrossRef
273.
McCormack SJ, Brazinski SE, Moore JL, et al. Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18. Oncogene 1997; 15: 265–74PubMedCrossRef
274.
Cotter TG. BCR-ABL: an anti-apoptosis gene in chronic myelogenous leukemia. Leuk Lymph 1995; 18: 231–6CrossRef
275.
Van Etten RA, Jackson P, Baltimore D. The mouse type IVc-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 1989; 58: 669–78PubMedCrossRef
276.
Kipreos ET, Wang JYJ. Cell cycle-regulated binding of c-Abl tyrosine kinase to DNA. Science 1992; 256: 382–5PubMedCrossRef
277.
Jackson P, Baltimore D. N-terminal mutations activates the leukemogenic potential of the myristoylated form of c-abl. EMBOJ 1989; 8: 449–56
278.
Muller AJ, Young JC, Pendergast AM, et al. BCR first exon sequences specifically activates the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome positive human leukemias. Mol Cell Biol 1991; 11: 1785–92PubMed
279.
Oppi C, Shore SK, Reddy EP. Nucleotide sequence of testis-derived cDNAs: implications for testis specific transcription and abl oncogene activation. Proc Natl Acad Sci U S A 1987; 84: 8200–4PubMedCrossRef
280.
Sawyers CL, McLaughlin J, Goga A, et al. The nuclear tyrosine kinase c-Abl negatively regulates cell growth. Cell 1994; 77: 121–31PubMedCrossRef
281.
Yuan ZM, Huang Y, Whang Y, et al. Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature 1996; 382: 272–4PubMedCrossRef
282.
Okabe M, Uehara Y, Nishima T, et al. in vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against bcr/abl oncoprotein in mice bearing bcr/abl-transfected cells. Leuk Res 1994; 18: 867–73PubMedCrossRef
283.
Hanks S, Quinn AM, Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 1988; 241: 42–52PubMedCrossRef
284.
285.
Ihle JN, Witthuhn BA, Quelle FW, et al. Signalling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci 1994; 19: 222–7PubMedCrossRef
286.
Silvennoinen O, Schindler C, Schlessinger J, et al. Ras-independent growth factor signalling by transcription factor tyrosine phosphorylation. Science 1993; 261: 1736–9PubMedCrossRef
287.
Stahl N, Yancopoulos GD. The alphas, betas, and kinases of cytokine receptor complexes. Cell 1993; 74: 587–90PubMedCrossRef
288.
Velazquez L, Fellous M, Stark GR, et al. A protein tyrosine kinase in the interferon alpha/beta signalling pathway. Cell 1992; 70: 313–22PubMedCrossRef
289.
Watling D, Guschin D, Muller M, et al. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature 1993; 366: 166–70PubMedCrossRef
290.
Muller M, Briscoe J, Laxton C, et al. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and — gamma signal transduction. Nature 1993; 366: 129–35PubMedCrossRef
291.
Cance WG, Craven RJ, Weiner TM, et al. Novel protein kinases expressed in human breast cancer. Int J Cancer 1993; 54: 571–7PubMedCrossRef
292.
Miyazaki T, Kawahara A, Fujii H, et al. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 1994; 266: 1045–7PubMedCrossRef
293.
Rodig S, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998; 93: 373–83PubMedCrossRef
294.
Parganas E, Wang, D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93: 385–95PubMedCrossRef
295.
Neubauer H, Cumao A, Müller M, et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998; 93: 397–409PubMedCrossRef
296.
Shuai K, Stark GR, Kerr TM, et al. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 1993; 261: 1744–6PubMedCrossRef
297.
Leung S, Li X, Stark GR. STATs find that hanging together can be stimulating. Science 1996; 273: 750PubMedCrossRef
298.
Lutticken C, Wegenka UM, Yuan J, et al. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp 130. Science 1994; 263: 89–92PubMedCrossRef
299.
Pearse RN, Feinman R, Shuai K, et al. Interferon gamma-induced transcription of the high-affinity Fc receptor for IgG requires assembly of a complex that includes the 91-kDa subunit of transcription factor ISGF 3. Proc Natl Acad Sci U S A 1993; 90: 4314–8PubMedCrossRef
300.
Silvennoinen W, Witthuhn BA, Quelle FW, et al. Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc Natl Acad Sci U S A 1993; 90: 8429–33PubMedCrossRef
301.
Sadowski HB, Shuai K, Darnell JE, et al. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science 1993; 261: 1739–44PubMedCrossRef
302.
Ruff-Jamison S, Chen K, Cohen S. Induction by EGF and interferon-gamma of tyrosine phosphorylated DNA binding proteins in mouse liver nuclei. Science 1993; 261: 1733–6PubMedCrossRef
303.
Zachary I, Rozengurt E. Focal adhesion kinase (p125FAK): a point of convergence in the action of neuropeptides, integrins, and oncogenes. Cell 1992; 71: 891–4PubMedCrossRef
304.
Schaller MD, Hildebrand JD, Shannon JD, et al. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol 1994; 14: 1680–8PubMed
305.
Hanks SK, Calalb MB, Harper MC, et al. Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. Proc Natl Acad Sci U S A 1992; 89: 8487–91PubMedCrossRef
306.
Tani T, Von Koskull H, Virtanan I. Focal adhesion kinase pp125-FAK is associated with both intercellular junctions and matrix adhesion sites in vivo. Histochem Cell Biol 1996; 105: 17–25PubMedCrossRef
307.
Aprikian AG, Tremblay L, Han K, et al. Bombesin stimulates the motility of human prostate-carcinoma cells through tyrosine phosphorylation of focal adhesion kinase and of integrin-associated proteins. Int J Cancer 1997; 72: 498–504PubMedCrossRef
308.
Duncan MD, Harmon JW, Duncan KLK. Actin disruption inhibits bombesin stimulation of focal adhesion kinase (pp125-FAK) in prostate carcinoma. J Surg Res 1996; 63: 359–63PubMedCrossRef
309.
Matsumoto K, Matsumoto J, Nakamura T, et al. Hepatocyte growth factor-scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125-FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. J Biol Chem 1994; 269: 31807–13PubMed
310.
Jiang WG, Hiscox S, Nakamura T, et al. Hepatocyte growth factor induces tyrosine phosphorylation of focal adhesion kinase (FAK) and paxillin and enhances cell-matrix interactions. Oncol Rep 1996; 3: 819–23PubMed
311.
Canbay E, Norman M, Kilic E, et al. Prolactin stimulates the JAK2 and focal adhesion kinase pathways in human breast carcinoma T47-D cells. Biochem J 1997; 324: 231–6PubMed
312.
Yu G, Smithgall TE, Glazer RI. K562 leukemia cells transfected with the human c-fes gene acquire the ability to undergo myeloid differentiation. J Biol Chem 1989; 264: 10276–81PubMed
313.
Van de Ven WJM. The protein kinases: Fes/Fps. In: Hardie G, Hanks S, editors. The protein kinase facts book. New York: Academic Press, 1995: 92–4
314.
Hao QL, Heisterkamp N, Groffen J. Isolation and sequence analysis of a novel human tyrosine kinase. Mol Cell Biol 1989; 9: 1587–93PubMed
315.
Feldman RA, Gabrilove JL, Tam JP, et al. Specific expression of the human cellular fps/fes-encoded protein NCP92 in normal and leukemic myeloid cells. Proc Natl Acad Sci U S A 1985; 82: 2379–83PubMedCrossRef
316.
MacDonald I, Levy J, Pawson T. Expression of the mammalian c-fes protein in hematopoietic cells and identification of a distinct fes-related protein. Mol Cell Biol 1985; 5: 2543–51PubMed
317.
Slamon D, de Kemion JR, Verma IM, et al. Expression of cellular oncogenes in human malignancies. Science 1984; 224: 256–62PubMedCrossRef
318.
Greer P, Haigh J, Mbamalu G, et al. The fps/fes protein-tyrosine kinase promotes angiogenesis in transgenic mice. Mol Cell Biol 1994; 14: 6755–63PubMed
319.
Sithanandam G, Kolch W, Duh FM, et al. Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies. Oncogene 1990; 5: 1775–80PubMed
320.
Marais R, Light Y, Paterson HF, et al. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic Ras and tyrosine kinases. J Biol Chem 1997; 272: 4378–83PubMedCrossRef
321.
Bernards A. Neurofibromatosis type I and Ras-mediated signalling: filling in the GAPs. Biochim Biophys Acta 1995; 1242: 43–59PubMed
322.
Adari H, Lowy DR, Willumsen BF, et al. Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. Science 1988; 240: 518–21PubMedCrossRef
323.
Rodriguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidylinositol-3-OH kinase as a direct target of ras. Nature 1994; 370: 527–32PubMedCrossRef
324.
Willumsen BM, Vass WC, Velu TJ, et al. Mutational analysis of a ras catalytic domain. Mol Cell Biol 1991; 11: 6026–33PubMed
325.
Amar S, Glozman A, Chung D, et al. Selective inhibition of oncogenic ras-p21 in vivo by agents that block its interaction with jun-N-kinase (JNK) and jun proteins: implications for the design of selective chemotherapeutic agents. Cancer Chemother Pharmacol 1997; 41: 79–85PubMedCrossRef
326.
Hiwasa T. Ras inhibitors [review]. Oncol Rep 1994; 3: 7–14
327.
Marais R, Light Y, Mason C, et al. Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C [published erratum appears in Science 1998; 280: 987]. Science 1998; 280: 109–12PubMedCrossRef
328.
Blagosklonny MV, Giannakakou P, El-Deiry WS, et al. Raf-1/bcl-2 phosphorylation: a tep from microtubule damage to cell death. Cancer Res 1997; 57: 103–5
329.
Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996; 87: 629–38PubMedCrossRef
330.
Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis [published erratum appears in Nat Med 1997; 3: 934]. Nat Med 1997; 3: 614–20PubMedCrossRef
331.
332.
Ouyang H, Furukawa T, Abe T, et al. The Bax gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach and endometrium. Clin Cancer Res 1998; 4: 1071–4PubMed
333.
Brimmell M, Mendiola R, Mangion J, et al. Bax frameshift mutations in cell lines derived from human haematopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. Oncogene 1998; 16: 1803–12PubMedCrossRef
334.
Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682–9PubMed
335.
Kiaris H, Spandidos DA. Mutations or ras genes in human tumours [review]. Int J Oncol 1995; 7: 413–21PubMed
336.
Ravi R, Bedi A, Fuchs EJ, et al. CD95 (Fas)-induced caspase-mediated proteolysis of NF-κB. Cancer Res 1998; 58: 882–6PubMed
337.
Sithanandam G, Dean M, Brennscheidt U, et al. Loss of heterozygosity at the c-raf locus in small cell lung carcinoma. Oncogene 1989; 4: 451–5PubMed
338.
Berger DH, Jardines, LA, Chang H, et al. Activation of Rf-1 in human pancreatic adenocarcinoma. J Surg Res 1997; 69: 199–204PubMedCrossRef
339.
Callans LS, Naama H, Khandelwal M, et al. Raf-1 protein expression in human breast cancer cells. Anns Surg Oncol 1995; 2: 38–42CrossRef
340.
Patel BK, Ray S, Whiteside TL, et al. Correlation of constitutive activation of raf-1 with morphological transformation and abrogation of tyrosine phosphorylation of distinct sets of proteins in human squamous carcinoma cells. Mol Carcinogen 1993; 18: 1–6CrossRef
341.
Riva C, Lavieille JP, Reyt E, et al. Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance. Eur J Cancer Oral Oncol 1995; 31B (Pt B): 384–91CrossRef
342.
Eggstein S, Manthey G, Hirsch T, et al. Raf-1 kinase, epidermal growth factor receptors, and mutant Ras proteins in colonic carcinomas. Dig Dis Sci 1996; 41: 1069–75PubMedCrossRef
343.
Okuda K, Matulonis U, Salgia R, et al. Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp Hematol 1994; 22: 1111–7PubMed
344.
Schmidt CA, Oettle H, Ludwig WD, et al. Overexpression of the Raf-1 proto-oncogene in human myeloid leukemia. Leuk Res 1994; 18:409–13PubMedCrossRef
345.
Callans LS, Naama H, Khandelwal M, et al. Raf-1 phosphorylation in human breast cancer cells (Meeting abstract). Soc. Surg. Oncol., 46th Annual Cancer Symposium in Conjunction with Society of Head and Neck Surgeons; 1993 March 18–21, Los Angeles (CA), 20
346.
Patel BK, Kasid U. Nucleotide sequence analysis of c-raf-1 cDNA and promoter from a radiation-resistant human squamous carcinoma cell line: deletion within exon 17. Mol Carcinogen 1993; 8: 7–12CrossRef
347.
Storm SM, Rapp UR. Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors. Toxicology Lett 1993; 67: 201–10CrossRef
348.
Teyssier JR, Henry I, Dozier C, et al. Recurrent deletion of the short arm of chromosome 3 in human renal cell carcinoma: shift of the c-raf 1 locus. J Natl Cancer Inst 1986; 77: 1187–95PubMed
349.
Ikeda S, Sumii H, Akiyama K, et al. Amplification of both c-myc and c-raf-1 oncogenes in a human osteosarcoma. Jpn J Cancer Res 1989; 80: 6–9PubMedCrossRef
350.
Xerri L, Charpin C, Hassoun J, et al. Mos oncogene expression in human ovarian tumors. Anticancer Res 1991; 11: 1629–34PubMed
351.
Lidereau R, Mathieu-Mahul D, Theillet C, et al. Presence of an allelic EcoRI restriction fragment of the c-mos locus in leukocyte and tumor cell DNAs of breast cancer patients. Proc Natl Acad Sci U S A 1985; 82: 7068–70PubMedCrossRef
352.
Parkar MH, Seid JM, Stringer BM, et al. Abnormal expression of the MOS proto-oncogene in human thyroid medullary carcinoma. Cancer Lett 1988; 15: 185–9CrossRef
353.
Lidereau R, Cole ST, Larsen CJ, et al. A single point mutation responsible for c-mos polymorphism in cancer patients. Oncogene 1987; 1: 235–7PubMed
354.
Csaikl F, Mullauer L, Schwabe M, et al. Mutations of c-myc and c-mos genes lead to aberrant transcription of c-myc [abstract]. Blut 1987; 55: 244
355.
Staal SP Molecular cloning of the AKT oncogene and its human homologous AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci U S A 1987; 84: 5034–7PubMedCrossRef
356.
Ahmad S, Singh N, Bellacosa A, et al. Endogenous regulation of the protooncogene protein serine-threonine kinase, c-AKT by estradiol and insulin growth factor-1 in MCF-7 breast carcinoma cells [abstract]. Proc Am Assoc Cancer Res 1998; 38: 232
357.
Schmidt CM, McKillop IH, Cahill PA, et al. Functionally significant Gi-protein linked MAPK pathway in primary human hepatocellular carcinoma [abstract]. Hepatol 1997; 26: 263ACrossRef
358.
Takahashi T, Murohashi I, Kishimoto K, et al. Hyperexpression of mitogen-activated protein kinase (p42-p44 MAPK) in malignant lymphoid neoplasms [abstract]. Blood 1997; 90: 165B
359.
Attar BM, Atten MJ, Holian O. MAPK activity is down-regulated in human colon adenocarcinoma: correlation with PCK activity. Anticancer Res 1996; 16: 395–9PubMed
360.
Frexes-Steed M, Woodard B A, Kern S, et al. Growth regulation by the ras-MAPK pathway in human pancreatic ductal carcinoma [abstract]. Gastroenterol 1997; 112: A564
361.
Yee D, Gooch JL, Jackson JG. IGF-I, insulin, and IL4 activated IRS 1 in human breast cancer cells: Differential IRS 1 tyrosine phosphorylation by IGF-I is associated with increased MAPK and PI3K activation [abstract]. Proc Am Assoc Cancer Res Ann Meeting 1997; 38: 435
362.
Sun SC, Elwood J, Beraud C, et al. Human T-cell leukemia-virus type-I tax activation of NF-kappa-B/Rel involves phosphorylation and degradation of I-kappa-B-alpha and rela (p65)-mediated induction of the c-rel gene. Mol Cell Biol 1994; 14: 7377–84PubMed
363.
Bours V, Dejardin E, Goujon-Letawe F, et al. The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. Biochem Pharmacol 1994; 47: 145–9PubMedCrossRef
364.
Gilmore TD. Role of rel family genes in normal and malignant lymphoid cell growth. Cancer Surv 1992; 15: 69–87PubMed
365.
Feuillard J, Korner M, Israel A, et al. Differential nuclear localization of p50, p52, and RelB proteins in human accessory cells of the immune response in situ. Eur J Immunol 1996; 26: 2547–51PubMedCrossRef
366.
Sovak MA, Bellas RE, Kim DW, et al. Aberrant nuclear factor-kappa-B-Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997; 100: 2952–60PubMedCrossRef
367.
Dejardin E, Bonizzi G, Bellahcene A, et al. Highly-expressed p100/p52 (NFKB2) sequesters other NF-kappa B -related proteins in the cytoplasm of human breast cancer cells. Oncogene 1995; 11: 1835–41PubMed
368.
Maxwell SA, Johnson M, Mukhopadhyay T. Expression and regulation of nuclear factor-kappa B (NFκ-B)/REL in non-small cell lung carcinoma and transformed cell lines [abstract]. Int J Oncol 1995; 7: 984
369.
Visconti R, Cerutti J, Battista S, et al. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NF-kappa-B p65 protein expression. Oncogene 1997; 15: 1987–94PubMedCrossRef
370.
Mukhopadhyay T, Roth JA, Maxwell SA. Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. Oncogene 1995; 11: 999–1003PubMed
371.
Maxwell SA, Mukhopadhyay T. A novel NF-kappa B p65 spliced transcript lacking exons 6 and 7 in a non-small cell lung carcinoma cell line. Gene 1995; 166: 399–400CrossRef
372.
Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappa-B-RelA activation is required for proliferation and survival of Hodgkin’s disease tumor cells. J Clin Invest 1997; 100: 2961–9PubMedCrossRef
373.
Nakshatri H, Bhat-Nakshatri P, Martin DA, et al. Constitutive activation of NF-kappa-B during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997; 17: 3629–39PubMed
374.
Trecca D, Guerrini L, Frachhiolla NS, et al. Identification of a tumor-associated mutant of the NF-kappa B RelA gene with reduced DNA-binding and transactivating activities. Oncogene 1997; 14: 791–9PubMedCrossRef
375.
Yew N, Strobel M, Vande Woude GF. Mos and the cell cycle: the molecular basis of the transformed phenotype. Curr Opin Genet Devel 1993; 3: 19–25CrossRef
376.
Sagata N, Watanabe N, Vande Woude GF, Ikawa Y. The c-mos proto-oncogene product is a cytostatic factor responsible for meiotic arrest in vertebrate eggs. Nature 1989; 342: 512–8PubMedCrossRef
377.
Vande Woude GF. Mos gen products (vertrebrates). In: Hardie G, Hanks S, editors. The protein kinase facts book. New York: Academic Press, 1995: 358–60
378.
Nebreda AR, Hill C, Gomez N, et al. The protein kinase mos activates MAP kinase kinase in vitro and stimulates the MAP kinase pathway in mammalian somatic cells in vivo. FEBS Lett 1993; 333: 183–7PubMedCrossRef
379.
Pham CD, Arlinghaus RB, Zheng CF, et al. Characterization of mek1 phosphorylation by the v-mos protein. Oncogene 1995; 10: 1683–8PubMed
380.
Marshall CJ. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Dev 1994; 4: 82–9PubMedCrossRef
381.
Davis RJ. MAPKs: new JNK expands the group. Trends Biochem 1994; 19: 470–3CrossRef
382.
Waskiewicz AJ, Cooper JA. Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Curr Opin Cell Biol 1995; 7: 798–805PubMedCrossRef
383.
Matsuda S, Kawasaki H, Moriguchi T, et al. Activation of protein kinase cascades by osmotic shock. J Biol Chem 1995; 270: 12781–6PubMedCrossRef
384.
Ichijo H, Nishida E, Irie K, et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997; 275: 90–4PubMedCrossRef
385.
Maeda T, Takekawa M, Saito H. Activation of yeast PBS2 MAPKK by MAPKKKs or by binding of an SH3-containing osmosensor. Science 1995; 269: 554–8PubMedCrossRef
386.
Wang TH, Henley DC, Ichijo H, et al. Involvement of Ras and apoptosis signal-regulating kinase (ASK-1) in activation of the JNK/SAPK cascade by treatment with paclitaxel or vinblastine [abstract]. Proc Am Assoc Cancer Res 1998; 39: 89
387.
Saitoh M, Nishitoh H, Fuji M, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998; 17(9): 2596–606PubMedCrossRef
388.
Ko YG, Seol WG, Kim TH, et al. Functional interaction or human glutaminyl-t RNA synthetase and apoptosis signal-structure kinsase (Ask) 1 [abstract]. Mol Biol Cell 1999; 10: 1909
389.
Alessi DR, Saito Y, Campbell DG, et al. Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf−1. EMBO J 1994; 13: 1610–9PubMed
390.
Vaillancourt RR, Gardner AM, Johnson GL. B-Raf-dependent regulation of the MEK-1/mitogen-activated protein kinase pathway in PC12 cells and regulation by cyclic AMP. Mol Cell Biol 1994; 14: 6522–30PubMed
391.
Papin CA, Eychene A, Brunet G, et al. B-raf protein isoforms interact with and phosphorylate mek-1 on serine residue-218 and residue 222. Oncogene 1995; 10: 1647–51PubMed
392.
Seger R, Ahn NG, Posada J, et al. Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells. J Biol Chem 1992; 257: 14373–81
393.
Anderson NG, Mailer JL, Tonks NK, et al. Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature 1990; 343: 651–3PubMedCrossRef
394.
Evan G, Wyllie A, Gilbert C, et al. Induction of apoptosis in fibroblasts by the c-myc protein. Cell 1992; 69: 119–25PubMedCrossRef
395.
396.
Franke TF, Kaplan DR, Cantley LC. P13’K: downstream AKTion blocks apoptosis. Cell 1997; 88: 435–7PubMedCrossRef
397.
Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell intrinsic death machinery. Cell 1997; 91: 231–41PubMedCrossRef
398.
Marte BM, Downward J. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci 1997; 22: 355–8PubMedCrossRef
399.
Van Antwerp DJ, Martin SJ, Kafri T, et al. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996; 274: 787–89PubMedCrossRef
400.
Malinin NL, Boldin MP, Kovalenko AV, et al. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature 1997; 385: 540–4PubMedCrossRef
401.
402.
Woronicz JD, Gao X, Cao Z, et al. IκB kinase-ß: NF-κB activation and complex formation with IkB kinase-α and NIK. Science 1997; 278: 866–9PubMedCrossRef
403.
Verma IM, Stevenson JK, Schwartz EM, et al. Rel/NF kappa B/I kappa B family: intimate tales of association and disassociation. Genes Dev 1995; 9: 2723–35PubMedCrossRef
404.
Beuerle PA, Baltimore D. Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. Cell 1988; 53: 211–7CrossRef
405.
Haskill S, Berg AA, Tompkins SM, et al. Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity. Cell 1991; 65: 1281–9PubMedCrossRef
406.
Ganchi PA, Sun SC, Greene WC, et al. I kappa B/MAD-3 masks the nuclear localization signal of NF-kappa B p65 and requires the transactivation domain to inhibit NF-kappa B p65 DNA binding. Mol Biol Cell 1992; 3: 1339–52PubMed
407.
Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995; 26: 86–91PubMedCrossRef
408.
Brockman JA, Scherer DC, McKinsey TA, et al. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. Mol Cell Biol 1995; 15: 2809–18PubMed
409.
Traenckner EB, Pahl HL, Henkel T, et al. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J 1995; 14: 2876–83PubMed
410.
Chen Z, Hagler J, Palombella VJ, et al. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 1995; 9: 1586–97PubMedCrossRef
411.
Mercurio F, Zhu H, Murray BW, et al. IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science 1997; 278: 860–6PubMedCrossRef
412.
DiDonato JA, Hayakawa M, Rothwarf DM, et al. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 1997; 388: 548–54PubMedCrossRef
413.
Chen RH, Tung R, Abate C, et al. Cytoplasmic to nuclear signal transduction by mitogen-activated protein kinase and 90 kDa ribosomal S6 kinase. Biochem Soc Trans 1993; 21: 895–900PubMed
414.
Xing J, Ginty DD, Greenberg ME. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 1996; 273: 969–3CrossRef
415.
Ghoda L, Lin X, Greene WC. The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IκBα and stimulates its degradation in vitro. J Biol Chem 1997; 272: 21281–8PubMedCrossRef
416.
Boldin M, Varfolomeev EE, Pancer Z, et al. A novel protein that interacts with the death domain of Fas/APO 1 contains a sequence motif related to the death domain. J Biol Chem 1995; 270: 7795–8PubMedCrossRef
417.
Peter ME, Kischkel FC, Hellrandt S, et al. CD95 (APO-1/Fas)-associating signaling proteins. Cell Death Differ 1996; 3: 161–70PubMed
418.
Alnemri ES, Livingson DJ, Nicholson DW, et al. Human ICE/CED-3 protease nomenclature [letter]. Cell 1996; 87: 171PubMedCrossRef
419.
Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996; 85: 817–27PubMedCrossRef
420.
Boldin MP, Goncharov TM, Goltsev YV, et al. Involvement of MACH, a novel MORT-1/FADD-interacting protease, in Fas/APO-1 and TNF receptor-induced cell death. Cell 1996; 85: 803–15PubMedCrossRef
421.
Kischkel FC, Hellbrandt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins (CAP) form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995; 14: 5579–88PubMed
422.
Medema JP, Scaffidi C, Kischkel FC, et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 1997; 16: 2794–804PubMedCrossRef
423.
Froelich CJ, Dixit VM, Yang X. Lymphocyte granule-mediated apoptosis: matters of viral mimicry and deadly proteases. Immunol Today 1998; 19: 30–6PubMedCrossRef
424.
Müller R, Mumberg D, Lucibello FC. Signals and genes in the control ofthe cell cycle progression. BBA 1993; 1155: 151–79PubMed
425.
Müller R. Transcriptional regulation during the mammalian cell cycle. Trends Genet 1995; 11: 173–8PubMedCrossRef
426.
Bürger C, Wick M, Brüsselbach S, et al. Differential induction of ‘metabolic genes’ after mitogen stimulation and during normal cell cycle progression. J Cell Sci 1994; 107: 241–52PubMed
427.
428.
429.
Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and cdk inhibitors come of age. Cell 1994; 79: 573–82PubMedCrossRef
430.
Peter M, Herskowitz I. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 1984; 79: 181–4CrossRef
431.
Hannon GF, Beach D. p15INK4B is a potential effector of TGFfl-induced cell cycle arrest. Nature 1994; 371: 257–61PubMedCrossRef
432.
Guan KL, Jenkins CW, Li Y, et al. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related cdk6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994; 8: 2939–52PubMedCrossRef
433.
Noda A, Ning Y, Venable SF, Pereira-Smith OM, et al. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994; 211: 90PubMedCrossRef
434.
DeBondt HL, Rosenblatt J, Jancarik J, et al. Crystal structure of cyclin-dependent kinase 2. Nature 1993; 363: 595–602CrossRef
435.
Lees EM, Harlow E. Sequences within the conserved cyclin box of human cyclin A are sufficient for binding to and activation of cdc2 kinase. Mol Cell Biol 1993; 13: 1194–201PubMed
436.
Endicott JA, Nurse P, Johnson LN. Mutational analysis supports a structural model for the cell cycle kinase p 34. Protein Eng 1994; 7: 243–53PubMedCrossRef
437.
Solomon MJ. The function(s) of CAK, the p34cdc2-activating kinase. Trends Biochem Sci 1994; 19: 496–500PubMedCrossRef
438.
Ducommun B, Brambilla P, Felix MA, et al. cdc2 phosphorylation is required for its interaction with cyclin. EMBO J 1991 10: 3311–9PubMed
439.
Desai D, Wessling HC, Fisher RP, et al. Effects of phosphorylation by CAK on cyclin binding by cdc2 and cdk 2. Mol Cell Biol 1995; 15: 345–50PubMed
440.
Zhang J, Sanchez RJ, Wang S, et al. Substrate specificity of cdc2 kinase from human HeLa cells as determined with synthetic peptides and molecular modelling. Arch Biochem Biophys 1994; 351: 415–24CrossRef
441.
Rickert P, Seghezzi W, Shanahan F, et al. Cyclin C/cdk8 is a novel CTD kinase associated with RNA polymerase II. Oncogene 1996; 12: 2631–40PubMed
442.
Galaktionov K, Beach D. Specific activation of cdc25 tyrosine phosphatases by B-type cyclin: evidence for multiple roles of mitotic cyclins. Cell 1991; 67: 1181–94PubMedCrossRef
443.
Zheng XF, Ruderman JV. Functional analysis of the P box, a domain in cyclin B required for the activation of Cdc 25. Cell 1993; 78: 155–64
444.
Karp JE, Broder S. Molecular foundations of cancer: new targets for intervention. Nat Med 1995; 1: 309–20PubMedCrossRef
445.
Soufir N, Avril MF, Chompret A, et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. Human Mol Genetics 1998; 7: 209–16CrossRef
446.
Wölfel T, Hauer M, Schneider J, et al. A p16INK4a insensitive CDK4 mutant targeted by cytolytic T lymphocyte in a human melanoma. Science 1995; 269: 2181–4CrossRef
447.
Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A 1993; 90: 1112–26PubMedCrossRef
448.
Keyomarsi K, O’Leary N, Molnar G, et al. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994; 54: 380–5PubMed
449.
450.
Mulligan GJ, Jacks T. The retinoblastoma gene family: cousins with overlapping interests. Trends Genet 1998; 14: 223PubMedCrossRef
451.
Grana X, Garriga J, Mayol X. Role of the retinoblastoma protein family, pRb, p107 and p130 in the negative control of cell growth. Oncogene 1998; 17: 3365–83PubMedCrossRef
452.
Sedlacek HH, Czech J, Naik R, et al. Flavopiridol (L86-8275; NSC 64890), a new kinase inhibitor for tumor therapy. Int J Oncol 1996; 9: 1143–68PubMed
453.
Lipson KE, Wang X, Chen H, et al. SU101, and not its major metabolite, inhibits PDGF-dependent receptor tyrosine phosphorylation, cell cycle progression, and human tumor cell growth. Proc Am Assoc Cancer Res 1998; 39: 558
454.
Blaskovich MA, Wang H, Hamilton AD, et al. Selective inhibition of PDGF-dependent receptor tyrosine phosphorylation and MAP kinase activation by tryptophan derivatives [abstract]. Proc Am Assoc Cancer Res 1998; 39: 559
455.
Vincent PW, Akinson BE, Zhou H, et al. Characterization of the in vivo activity of a novel EGF receptor family kinase inhibitor, PD 169414 [abstract]. Proc Am Assoc Cancer Res 1998; 39: 560
456.
Miller PE, Robinson J, Moyer JD, et al. CP-358,774, a selective EGFR kinase inhibitor, inhibits phosphorylation of SHC and retinoblastoma protein in human tumor xenografts [abstract]. Proc Am Assoc Cancer Res 1998; 39: 560
457.
Mett H, Buchdunger E. Müller M. CGP 59326, a potent protein tyrosine kinase (PTK) inhibitor which selectively blocks growth of epidermal growth factor receptor (EGFR) expressing tumor cells [abstract]. Proc Am Assoc Cancer Res 1998; 39: 560
458.
Fong TAT, Shawver LK, App H, et al. SU5416: a potent and selective Flk-1/KDR kinase inhibitor that blocks Flk-1 phosphorylation, endothelial cell mitogenesis and tumor growth. Proc Am Assoc Cancer Res 1998; 39: 560
459.
Kraker AJ, Moore CW, Hartl BG, et al. Effects of c-src selective pyrido[2,3-d]-pyrimidine tyrosine kinase inhibitors on the phophorylation of p130cas, paxillin, and STAT3 and on proliferation in human carcinoma cell lines [abstract]. Proc Am Assoc Cancer Res 1998; 39: 559
460.
Gay B, Furet P, Fretz H, et al. Design of a highly potent inhibitor of Grb2 SH2 domain with cellular and in vivo activity [abstract]. Proc Am Assoc Cancer Res 1998; 39: 559
461.
Buchdunger E, Cioiffi C, Cozens R, et al. Preclinical evaluation of CGP 57148, a potent protein-tyrosine kinase inhibitor as a therapeutic agent for PH+ leukemias and solid tumors [abstract]. Proc Am Assoc Cancer Res 1998; 39: 559
462.
Heimbrook DC, Huber HE, Stordivant SM, et al. Identification of potent, selective kinase inhibitors of Raf Proc Am Assoc Cancer Res 1998; 39: 558
463.
Meyer T, Zimmermann J, Geiger T, et al. CGP 60474, a protein kinase inhibitor with potent antitumor activity in vivo at well tolerated doses [abstract]. Proc Am Assoc Cancer Res 1998; 39: 558
464.
Senderowicz A, Headlee D, Stinson S, et al. Phase I trial of a novel cyclin-dependent kinase inhibitor flavopiridol in patients with refractory neoplasms. Clin Oncol 1998; 16(9): 2986–99
465.
Werner JL, Kelsen DP, Karpeh M, et al. The cyclin dependent kinase inhibitor flavopiridol is an active and unexpectedly toxic agent in advanced gastric cancer [abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology: 1998 May 16–19; Los Angeles, 234a
466.
Schwartz GK, Werner JL, Maslak P, et al. Flavopiridol enhances the biological effects of paclitaxel: a phase I trial in patients with advance solid tumors. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology: 1998 May 16–19; Los Angeles, 188a
467.
Parker BW, Senderowicz AM, Nieves-Neira W, et al. DNA fragmentation and apoptosis of lymphoma and prostate cancer cell lines after flavopiridol treatment [abstract]. Proc Am Assoc Cancer Res 1996; 37: 398
468.
Schwartz GK, Farsi K, Danso D, et al. The protein kinase C inhibitors UCN-01 and flavopiridol significantly enhance the cytotoxic effect of chemotherapy by promoting apoptosis in gastric and breast cancer cells [abstract]. Proc Am Soc Oncol 1996; 15: 501
469.
Brüsselbach S, Nettelbeck DM, Sedlacek HH, et al. Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells. Int J Cancer 1998; 77: 146–52PubMedCrossRef
470.
Bible KC, Kaufmann SM. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 1996; 56: 4856–61PubMed
471.
Simizu S, Imoto M, Masuda N, et al. Involvement of hydrogen peroxide production in erbstatin-induced apoptosis in human small cell lung carcinoma cells. Cancer Res 1996; 56: 4978–82PubMed
472.
Palumbo GA, Yarom N, Gazit A, et al. The tyrphostin AG17 induces apoptosis and inhibition of cdk2 activity in a lymphoma cell line that overexpresses bcl-2. Cancer Res 1997; 57: 2434–9PubMed
473.
Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57: 4838–48PubMed
474.
Wei Y, Zhao X, Kariya Y, et al. Induction of apoptosis by quercetin: involvement of heat shock protein. Cancer Res 1994; 54: 4952–7PubMed
475.
Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987; 262: 5592–5PubMed
476.
Yamashita Y, Kawada S, Nakano H. Induction of mammalian topoisomerase II-dependent DNA cleavage by non-intercalative flavonoids, genistein, and phorbol. Biochem Pharmacol 1990; 39: 187–93CrossRef
477.
Constantinou A, Kiguchi K, Hubennan E. Induction of differentiation and DNA strand breakage in human HL-60 and K-562 leukemia cells by genistein. Cancer Res 1990; 50: 2618–24PubMed
478.
Okura A, Arakawa H, Oka H, et al. Effect of genistein on topoisomerase activity and on the growth of (Val 12) Ha-rastransformed NHI-3T3 cells. Biochem Biophys Res Commun 1988; 157: 183–9PubMedCrossRef
479.
Rao CV, Wang CX, Simi B, et al. Enhancement of experimental colon cancer by genistein. Cancer Res 1997; 57: 3717–22PubMed
480.
Zava DT, Duwe G. Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutr Cancer 1997; 27: 31–40PubMedCrossRef
481.
Sato S, Kohno K, Izumi H, et al. Differential effects of pKI H-7 on activation of human MDRI promoter. Cell Pharmacol 1995; 2: 153–7
482.
Li JJ, Westergaard C, Ghosh P, et al. Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response. Cancer Res 1997; 57: 3569–76PubMed
483.
Monia BP, Sasmor H, Johnston JF, et al. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci U S A 1996; 93: 15481–4PubMedCrossRef
484.
Monia BP, Johnston JF, Geiger T, et al. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 1996; 2: 668–75PubMedCrossRef
485.
Filgueira W, De Azevedo jr, Mueller-Dieckmann HJ, et al. Structural basis for specific and potency of a flavonoid inhibitor of human cdk2, a cell cycle kinase. Proc Natl Acad Sci U S A 1996; 93: 2735CrossRef
486.
Pollman MJ, Hall JL, Mann MJ, et al. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nature Med 1998; 4: 222–7PubMedCrossRef
487.
Kraemer HP, Sedlacek HH. The human tumor clonogenic assay for the prediction of tumor sensitivity. In: Beger HG, Büchler M, Reisfeld RA, et al., editors. Cancer therapy. Berlin: Springer Verlag, 1989: 244–7
488.
Jäger W, Zembsch B, Wolschann P, et al. Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver. Life Sci 1998; 62: 1861–73PubMedCrossRef
Metadata
Title
Kinase Inhibitors in Cancer Therapy
A Look Ahead
Author
Dr H. H. Sedlacek
Publication date
01-03-2000
Publisher
Springer International Publishing
Published in
Drugs / Issue 3/2000
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200059030-00004

Other articles of this Issue 3/2000

Drugs 3/2000 Go to the issue

Disease Management

A Review of the Epidemiology and Approaches to the Treatment of Social Anxiety Disorder

Leading Article

What is New in the Treatment of Multiple Sclerosis?

Adis New Drug Profile

Alosetron

Adis Drug Evaluation

Meropenem

Adis New Drug Profile

Alosetron

Adis Drug Evaluation

Docetaxel